KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Johnson & Johnson (JNJ) EBT (2016 - 2025)

Johnson & Johnson's EBT history spans 17 years, with the latest figure at $5.0 billion for Q4 2025.

  • For Q4 2025, EBT rose 27.76% year-over-year to $5.0 billion; the TTM value through Dec 2025 reached $32.6 billion, up 95.25%, while the annual FY2025 figure was $32.6 billion, 95.25% up from the prior year.
  • EBT for Q4 2025 was $5.0 billion at Johnson & Johnson, down from $7.5 billion in the prior quarter.
  • Across five years, EBT topped out at $13.6 billion in Q1 2025 and bottomed at -$1.3 billion in Q2 2023.
  • The 5-year median for EBT is $5.2 billion (2022), against an average of $5.0 billion.
  • The largest annual shift saw EBT plummeted 124.74% in 2023 before it surged 388.58% in 2024.
  • A 5-year view of EBT shows it stood at $3.8 billion in 2021, then soared by 34.37% to $5.2 billion in 2022, then decreased by 6.69% to $4.8 billion in 2023, then decreased by 19.46% to $3.9 billion in 2024, then increased by 27.76% to $5.0 billion in 2025.
  • Per Business Quant, the three most recent readings for JNJ's EBT are $5.0 billion (Q4 2025), $7.5 billion (Q3 2025), and $6.5 billion (Q2 2025).